Health — operanewsapp.
Category: biotech/medical
In this short video, filmed at ASTRO 2021, Siemens Healthineers’ Gabriel Haras introduces the company’s portfolio of artificial intelligence (AI)-based products. Such technologies support the entire care pathway for cancer patients, from screening and diagnostics to treatment and follow-up, including innovations such as AI-based autocontouring and generation of synthetic CT from an MRI scan for radiotherapy planning.
Next, Varian’s Kevin O’Reilly comments on the combining of Varian and Siemens Healthineers into one united company. He notes that the integration of AI capabilities has increased Varian’s ability to innovate, and will help accelerate its intelligent cancer care strategy: accelerating the path to treatment, increasing global access to care, exploiting data-driven insight and improving personalization.
2021 saw massive growth in the demand for edge computing — driven by the pandemic, the need for more efficient business processes, as well as key advances in the Internet of Things, 5G and AI.
In a study published by IBM in May, for example, 94 percent of surveyed executives said their organizations will implement edge computing in the next five years.
From smart hospitals and cities to cashierless shops to self-driving cars, edge AI — the combination of edge computing and AI — is needed more than ever.
German drugmaker BioNTech is enrolling patients in a clinical trial to test its mRNA vaccine for colon cancer relapse.
Part 2
In this video Dr. Lustgarten goes into more detail on what he tracks and how he does the analysis of the results. He emphasizes the importance of running your own tests, to not only look at one biomarker but to then combine that marker with other biomarkers, looking for what is optimal for you.
Dr. Michael Lustgarten is a scientist at the Tufts University Human Nutrition Research Center on Aging in Boston, Massachusetts. His research currently focuses on the role of the gut microbiome and serum metabolome on muscle mass and function in older adults.
In this series of interviews Dr Lustgarten shares his experience with his rigorous n of 1 experiment over the last 7 years and shows how we or anyone can conduct a similar trial by tracking food, exercise and sleep, measure results and derive relationships between them, with a goal of extending our healthspan.
Dr Lustgarten’s channel on YouTube: https://www.youtube.com/channel/UCT1UMLpZ_CrQ_8I431K0b-g.
***************************************************************
Health claims Disclosure: Information provided on this video is not a substitute for direct, individual medical treatment or advice. Please consult with your doctor first. Products or services mentioned in this video are not a recommendation.
Audio Copyright Disclaimer.
Please note that we have full authorization to the music that we used in our videos as they were created using the service WeVideo which provides the rights to the music. The rights are detailed in the terms of use that can be reviewed here https://www.wevideo.com/terms-of-use and any following inquiries should be addressed to [email protected].
*****************************************************************
If you would like to support our channel, we’d love a coffee…thank you! https://www.buymeacoffee.com/mhealthspan.
#DrLustgarten #longevity #healthspan #nof1 #experiment #excel #biomarkers
“How do we use these new innovative technologies to really mitigate disparities in diabetes outcomes?” asked Risa Wolf, a pediatric endocrinologist at Johns Hopkins Hospital.
Karlsruhe, germany and novato, CA, USA
The Forever Healthy Foundation and the Buck Institute for Research on Aging today announced a new partnership to advance early-stage discoveries at the Institute that show promise to reverse physiologic aging in humans. The focus will be on cutting-edge research aimed at the repair of age-related damage at the cellular and molecular level, a hallmark of the aging process. Forever Healthy will commit up to $1 million per year for five years to drive this innovation. The funding aims to advance early-stage research with high translational potential in order to speed up the transition from lab to product.
German entrepreneur and longevity pioneer Michael Greve founded his humanitarian Forever Healthy initiative with the mission of accelerating the development of therapies to impede the aging process and the diseases that accompany it. This mission is in perfect alignment with the Buck Institute, the first independent biomedical facility in the world focused solely on the biology of aging.
Scientists have successfully taught a collection of human brain cells in a petri dish how to play the video game “Pong” — kind of.
Researchers at the biotechnology startup Cortical Labs have created “ mini-brains ” consisting of 800,000 to one million living human brain cells in a petri dish, New Scientist reports. The cells are placed on top of a microelectrode array that analyzes the neural activity.
We think it’s fair to call them cyborg brains, Brett Kagan, chief scientific officer at Cortical Labs and research lead of the project, told New Scientist.
In the first episode of Humans+, Motherboard dives into the world of future prosthetics, and the people working on closing the gap between man and machine.
We follow Melissa Loomis, an amputee from Ohio, who had experimental nerve reversal surgery and is going to Johns Hopkins’ Applied Physics Lab to test out its latest Modular Prosthetic Limb, a cutting-edge bionic arm funded in part by DARPA. Neuro-interfacing machinery is a game changer in terms rehabilitating patients, but what possibilities do these advancements open for the future?
Follow MOTHERBOARD
Facebook: http://www.facebook.com/motherboardtv.
Twitter: http://twitter.com/motherboard.
Tumblr: http://motherboardtv.tumblr.com/
Instagram: http://instagram.com/motherboardtv.
More videos from the VICE network: https://www.fb.com/vicevideo
On October 15, 2020, the European Union imposed sanctions on six senior Russian officials and a leading Russian research institute over the alleged use of a nerve agent from the Novichok family in the poisoning of opposition leader Alexey Navalny. Russia dismissed as baseless the EU’s allegations that it had not complied with its obligations, under the convention it ratified in 1997, to discontinue its chemical weapons program. Russian officials said the country had nothing to do with Navalny’s poisoning and implied that if any party had used nerve agents on him, it would have been Western secret services. Vladimir Putin, who in 2017 had personally watched over the destruction of the last remaining Russian chemical weapons stash, ridiculed the findings of four separate laboratories, confirmed by the OPCW, that a Novichok-type organophosphate poison was identified in Alexey Navalny’s blood.
Two years earlier, in 2018, Russia had dismissed as unfounded allegations that its military intelligence had used Novichok to poison former Russian spy Sergei Skripal and his daughter. Similarly, Russia had then stated that it had no ongoing chemical weapons program and had destroyed all of its prior arsenals; while alluding that UK agencies may have used their own stash of Novichok to poison the Skripals in a false-flag operation.
A year-long investigation by Bellingcat and its investigative partners The Insider and Der Spiegel, with contributing investigations from RFE/RL, has discovered evidence that Russia continued its Novichok development program long beyond the officially announced closure date. Data shows that military scientists, who were involved with the original chemical weapons program while it was still run by the Ministry of Defense, were dispersed into several research entities which continued collaborating among one another in a clandestine, distributed R&D program. While some of these institutes were integrated with the Ministry of Defense – but camouflaged their work as research into antidotes to organophosphate poisoning – other researchers moved to civilian research institutes but may have continued working, under cover of civilian research, on the continued program.